Key Points
- Director Douglas Roeder bought 17,041 Senseonics shares at an average price of $10.32, spending about $175,863 and increasing his stake by 9.87% to 189,712 shares.
- Senseonics reported a quarterly loss of $0.50 per share, slightly worse than analysts’ $0.49 loss estimate, on revenue of $19.56 million.
- Analyst sentiment is mixed: MarketBeat’s consensus rating is Hold, with an average price target of $14.40; ratings include three Buys, three Holds, and one Sell.
Senseonics Holdings, Inc. (NASDAQ:SENS - Get Free Report) Director Douglas Roeder purchased 17,041 shares of the business's stock in a transaction that occurred on Friday, November 13th. The shares were purchased at an average price of $10.32 per share, for a total transaction of $175,863.12. Following the completion of the acquisition, the director owned 189,712 shares of the company's stock, valued at $1,957,827.84. The trade was a 9.87% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Senseonics Stock Up 3.0%
Shares of SENS stock opened at $10.90 on Tuesday. Senseonics Holdings, Inc. has a 52-week low of $4.79 and a 52-week high of $13.98. The company has a quick ratio of 6.40, a current ratio of 5.92 and a debt-to-equity ratio of 0.70. The company has a 50-day simple moving average of $9.20 and a two-hundred day simple moving average of $7.34.
Senseonics (NASDAQ:SENS - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Senseonics had a negative net margin of 204.01% and a negative return on equity of 186.11%. The firm had revenue of $19.56 million during the quarter. As a group, sell-side analysts forecast that Senseonics Holdings, Inc. will post -2.20 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Senseonics
Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in Senseonics by 60.6% in the third quarter. Goldman Sachs Group Inc. now owns 371,706 shares of the company's stock worth $3,780,000 after acquiring an additional 140,197 shares during the period. Empowered Funds LLC purchased a new position in Senseonics in the third quarter valued at about $621,000. Ieq Capital LLC purchased a new position in Senseonics in the third quarter valued at about $215,000. StoneX Group Inc. purchased a new position in Senseonics in the third quarter valued at about $128,000. Finally, Traynor Capital Management Inc. bought a new position in shares of Senseonics during the 3rd quarter valued at approximately $152,000. Institutional investors own 12.36% of the company's stock.
Analyst Ratings Changes
SENS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $14.00 target price on shares of Senseonics in a report on Tuesday, November 10th. Wall Street Zen raised Senseonics from a "sell" rating to a "hold" rating in a research report on Saturday. Mizuho lifted their price target on Senseonics from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, November 10th. Barclays boosted their price objective on Senseonics from $10.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 10th. Finally, Raymond James Financial upgraded Senseonics from an "underperform" rating to a "market perform" rating in a research note on Tuesday, November 10th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $14.40.
Check Out Our Latest Stock Report on Senseonics
About Senseonics
(
Get Free Report)
Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].